Understanding the treatment of HSDD is a crucial step in managing your sexual health. Vyleesi®, also known by its generic name bremelanotide, offers a unique approach for premenopausal women experiencing this specific type of sexual dysfunction. It’s designed to be used only when you anticipate sexual activity, giving you control over your treatment schedule.
This guide provides a clear, detailed overview of bremelanotide for women. We will explore what it is, how it works, who is an appropriate candidate, and what to expect from treatment. It is essential to consult with your healthcare provider for medical advice tailored to your personal health needs before starting any new medication.
If you are a premenopausal woman struggling with consistently low sexual desire that causes you distress, you are not alone. Acquired, generalized hypoactive sexual desire disorder (HSDD) is a recognized medical condition, and effective treatment options are available. This article serves as a comprehensive guide to bremelanotide for women, marketed under the brand name Vyleesi.
We will cover the essential information you need to understand this treatment. This includes its FDA-approved use, how it functions to improve sexual health, and its efficacy as demonstrated in clinical trials. We will also discuss the proper method of administration, potential side effects, and important safety warnings.
Our goal is to provide a clinically accurate and easy-to-understand resource. This will help you have an informed discussion with your healthcare provider about whether Vyleesi is a suitable choice for addressing your low sexual desire and improving your overall well-being.
Vyleesi for HSDD: A Practical Guide
What is Vyleesi (bremelanotide)?
Vyleesi is the brand name for bremelanotide injection, a prescription medicine approved by the U.S. Food and Drug Administration (FDA). It is specifically indicated for the treatment of HSDD in premenopausal women. This condition is defined as acquired, generalized HSDD, meaning the low desire developed after a period of normal sexual desire and occurs regardless of the situation or partner.
This medication is intended for women who experience marked distress or interpersonal difficulty due to their low sexual desire. It is important to note that HSDD must be diagnosed by a healthcare professional, and other potential causes for low desire must be ruled out.
Vyleesi is not intended to enhance sexual performance or for use in postmenopausal women or men. It is the first and only as-needed treatment that has been FDA-approved for this specific patient population, offering a unique option for managing this condition.
How it works to boost sexual desire
The precise mechanism by which Vyleesi works to increase sexual desire is not fully understood, but it is known to act on pathways in the brain. It is a melanocortin receptor agonist, which means it activates specific receptors in the central nervous system that are thought to play a role in regulating sexual arousal and desire.
Unlike treatments that work on hormones or blood flow, Vyleesi targets the brain's chemistry. Many women with HSDD describe their struggle as a persistent lack of interest in sex, which can point to an imbalance of chemicals in the brain. Vyleesi is designed to help address this imbalance.
By influencing these neural pathways, the medication helps improve sexual interest and can enhance overall sexual function. This action makes it a targeted treatment for the central nervous system component of HSDD, helping to restore desire in women who are distressed by its absence.
Why HSDD is different from other sexual health issues
Hypoactive sexual desire disorder (HSDD) is a distinct medical diagnosis, not just a temporary lull in libido. The FDA has approved Vyleesi specifically for "acquired, generalized" HSDD. "Acquired" means you previously had a satisfying level of sexual interest, and "generalized" means the low desire is not limited to a specific partner or situation. This makes HSDD different from situational low desire caused by stress or fatigue.
A key diagnostic criterion for HSDD is that the lack of hypoactive sexual desire must cause significant personal distress or relationship difficulties. It is not simply a low number on a chart but a condition that negatively impacts your quality of life. This separates it from natural fluctuations in libido that do not cause concern.
Furthermore, HSDD is not diagnosed if the sexual dysfunction is better explained by another medical or psychiatric condition, problems within the relationship, or as a side effect of medication. Vyleesi is intended to treat HSDD itself, not to improve sexual performance or address low desire stemming from these other issues.
Who it’s for (and who it’s not)
Determining if Vyleesi is the right choice for you involves understanding its specific indications and, just as importantly, its contraindications. The medication is approved for a very specific group of individuals to ensure both safety and effectiveness. A diagnosis of acquired, generalized HSDD is the first step.
This section will detail the FDA-approved patient population for Vyleesi. We will also cover why it is not recommended for certain groups and list the key contraindications, or situations where the drug should not be used, to help you have a productive conversation with your clinician about your low sex drive.
FDA-approved population: premenopausal women
Vyleesi is FDA-approved exclusively for premenopausal women who have been diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). The clinical trials that established the safety and efficacy of Vyleesi were conducted specifically in this population.
A good candidate is a woman who has not yet gone through menopause and who previously had a normal level of sexual desire but now experiences a persistent and troubling lack of it. This lack of desire must be present regardless of the type of sexual activity, situation, or partner.
The approval is narrow because the data supports its use for this group. If you are a premenopausal woman experiencing these specific symptoms, and they are causing you personal distress, you may be a candidate for Vyleesi. A thorough evaluation by a healthcare provider is necessary to confirm the diagnosis.
Why it’s not indicated for men or postmenopausal women
The FDA has explicitly stated that Vyleesi is not indicated for the treatment of HSDD in men or postmenopausal women. This limitation is based on the scope of the clinical research conducted for the drug's approval. The pivotal studies focused solely on premenopausal women, so the safety and effectiveness in other groups have not been established.
For postmenopausal women, the causes of low sexual desire can be different and more complex, often involving hormonal changes like vaginal dryness or other factors related to menopause. These issues may require different treatment approaches. Therefore, Vyleesi is not recommended as its benefits in this population are unknown.
Similarly, male sexual dysfunction has different underlying causes and approved treatments. The mechanism of Vyleesi has not been studied in men for this purpose. Sticking to the approved population ensures that the medication is used where it has been proven to be beneficial and safe.
Contraindications: who should avoid Vyleesi
There are specific situations and medical conditions, known as contraindications, where Vyleesi should not be used due to the risk of serious adverse reactions. It is crucial to share your complete medical history with your healthcare provider before starting this prescription medicine.
You should not use Vyleesi if you have:
-
Uncontrolled hypertension (high blood pressure): The medication can cause a temporary increase in blood pressure.
-
Known cardiovascular disease: Patients with existing heart or blood vessel disease should avoid this treatment.
These contraindications are in place because Vyleesi can transiently raise blood pressure and reduce heart rate. In individuals with pre-existing cardiovascular issues or uncontrolled high blood pressure, these effects could pose a significant health risk. Always ensure your doctor is aware of any heart conditions or blood pressure problems before considering Vyleesi.
When low desire may not require medication
It is important to recognize that not all instances of low sexual desire are caused by HSDD or require medication. Vyleesi is specifically not indicated if your low desire is a result of other identifiable factors. A proper diagnosis is key to finding the right solution.
Your healthcare provider will consider if your low desire is due to:
-
Co-existing medical conditions or a psychiatric condition like depression.
-
Problems within your relationship or dissatisfaction with your partner.
-
The effects of another medication, herbal supplement, or drug substance.
In these cases, the most appropriate treatment options would involve addressing the root cause. This could mean changing medications, seeking counseling, or managing an underlying health issue. Vyleesi is designed for when these other causes have been ruled out, confirming that the low desire is due to acquired, generalized HSDD.
How and when to use it (doses/month limits)
Proper use of Vyleesi is essential for achieving the best results while minimizing potential risks. Since it is designed for as-needed drug administration, understanding the correct timing, dosage limits, and injection technique is critical. This approach allows you to plan your treatment around anticipated sexual activity.
This section provides a step-by-step guide on how to use Vyleesi. We will cover the self-injection method, the recommended timing before intimacy, dose frequency limits, and what to do if you miss or exceed a dose. Following these instructions carefully will help ensure safe and effective use.
Vyleesi injection method: subcutaneous self-use
Vyleesi is a bremelanotide injection that you administer yourself using a pre-filled autoinjector pen. The injection is given subcutaneously, which means just under the skin. This method of drug administration is designed to be simple and convenient for at-home use.
Your healthcare provider will show you how to use the autoinjector correctly. The recommended injection site is the front of your thigh or your abdomen. It is important to rotate injection sites with each dose to avoid skin irritation.
The autoinjector delivers a single, pre-measured dose of 1.75 mg. You should not attempt to use the device if it appears damaged or if the medicine looks cloudy or contains particles. Always use a new pen for each injection and dispose of it properly after use.
Best timing before sexual activity
One of the key features of Vyleesi is its as-needed dosing schedule, which means it is not a daily medication. You should administer the injection at least 45 minutes before you anticipate engaging in sexual activity. This timing allows the medication sufficient time to work on the brain pathways that influence sexual arousal.
Planning is part of the process. Since the effects are not instantaneous, taking it in advance of potential sexual events helps ensure you are prepared when the moment feels right. This gives you the flexibility to use the treatment when you choose, rather than being on a rigid daily schedule.
Because it is used on-demand, you can align its use with your lifestyle and relationship dynamics. This patient-controlled timing is a significant advantage for many women, providing a sense of control over their treatment and their sex life.
Maximum number of doses per month
To ensure safety, there are strict limits on the dose frequency of Vyleesi. Your healthcare provider will instruct you to use no more than eight doses per month. This limitation is based on the data from clinical trials and is in place to minimize the risk of side effects.
This prescription medicine is not intended for daily use. The doses/month limits are a critical part of the safety profile, particularly concerning the potential for darkening of the skin (hyperpigmentation), which is more likely with more frequent use.
Adhering to this guideline is essential for your health and well-being. In clinical studies, most women used Vyleesi two to three times per month. If you feel the need to use it more often than recommended, you should discuss this with your doctor.
Safe spacing between injections
In addition to the monthly limit, there is also a rule for safe spacing between individual doses. You should not administer more than one dose of Vyleesi within a 24-hour period. This is a crucial safety measure to prevent an accumulation of the drug in your system.
This 24-hour waiting period is particularly important for minimizing the risk of more pronounced effects on your blood pressure and heart rate. Each dose can cause a temporary increase in blood pressure, and taking another dose too soon could amplify this effect. Proper drug administration includes respecting this interval.
Following this instruction helps ensure that your body has time to process the medication fully before another dose is introduced. This rule, combined with rotating the injection site, is a key part of using Vyleesi safely and effectively.
What happens if you skip or exceed a dose
Since Vyleesi is taken on an as-needed basis, there is no concern about a missed dose in the traditional sense. If you do not anticipate sexual activity, you simply do not take the medication. You do not need to make up for skipped opportunities.
However, exceeding the recommended dose is a serious concern. Taking more than one dose in 24 hours or more than eight doses in a month can increase your risk of adverse reactions.
-
Increased Risk of Side Effects: Overuse can lead to more severe or persistent nausea, headaches, or flushing.
-
Cardiovascular Effects: Taking doses too close together can cause more significant temporary increases in blood pressure.
-
Hyperpigmentation: The risk of skin darkening increases with more frequent use.
If you accidentally take more than the recommended dose, you should watch for any unusual side effects and contact your healthcare provider for advice.
Efficacy from pivotal trials
The approval of Vyleesi was based on the results of two large-scale, pivotal studies known as the RECONNECT studies. These clinical trials were designed to rigorously evaluate the effectiveness and safety of the medication in its target population of premenopausal women with HSDD.
The findings from these trials demonstrated that Vyleesi provided statistically significant improvements in key measures of sexual function. This section will review the evidence, including the impact on sexual desire scores and the reduction of distress, giving you a clear picture of what the data shows.
Overview of RECONNECT Phase 3 studies
The efficacy of Vyleesi was established in two identical Phase 3 pivotal studies called RECONNECT. These randomized, double-blind, placebo-controlled clinical trials involved over 1,200 premenopausal women diagnosed with acquired, generalized HSDD. The participants had an average age of 39 and were primarily White (86%) and Black (12%).
The trials were structured to measure changes in sexual desire and the distress associated with it over a 24-week period. Following this core study, nearly 80% of participants who completed it chose to enroll in a 52-week open-label extension study to continue treatment.
This robust study design provided strong evidence for the FDA's review. The key components of the core study are summarized below.
|
Study Component |
Description |
|
Participants |
Over 1,200 premenopausal women with acquired, generalized HSDD. |
|
Study Design |
Two identical randomized, double-blind, placebo-controlled trials. |
|
Core Study Duration |
24 weeks of treatment with either Vyleesi or a placebo. |
|
Extension Phase |
A 52-week open-label extension where patients could continue treatment. |
Increase in sexual desire scores (FSFI-D results)
A primary goal of the RECONNECT studies was to measure whether Vyleesi could increase sexual desire. This was evaluated using standardized questionnaires, including the Female Sexual Function Index desire domain (FSFI-D). The results showed a statistically significant improvement for women using Vyleesi compared to those using a placebo.
Participants treated with Vyleesi reported a meaningful increase in their level of sexual interest. This outcome directly addresses the core symptom of HSDD. The ability to restore desire is a critical measure of success for any HSDD treatment.
These findings confirm that Vyleesi works to improve desire, not just sexual frequency. The increase in FSFI-D scores provided clinical proof that the medication has a tangible effect on the central component of the disorder, helping women regain the interest in sex they had lost.
Reduction in distress linked to HSDD
Beyond improving desire, a key part of the treatment of HSDD is alleviating the emotional burden it causes. HSDD is defined not only by low desire but also by the significant distress women feel because of it. The RECONNECT studies measured this using the Female Sexual Distress Scale.
The results were clear: women who took Vyleesi experienced a significant reduction in the stress related to their sexual desire disorder. This is a crucial finding, as it shows the treatment addresses both the physical and emotional aspects of the condition. Reducing distress can improve self-esteem and overall quality of life.
By helping to lessen the anxiety and frustration associated with HSDD, Vyleesi offers a more complete therapeutic benefit. This dual action of increasing desire while simultaneously decreasing distress is what makes it an effective option for many women.
Response timelines: when improvements are seen
Improvements in sexual desire often become noticeable within the first month of treatment with bremelanotide, particularly for premenopausal women experiencing hypoactive sexual desire disorder (HSDD). As the body adapts to the medication, many report a gradual enhancement of sexual interest and arousal, leading to increased sexual activity. However, individual responses can vary, and it’s essential to communicate any side effects or concerns with a healthcare provider. Regular monitoring ensures that patients receive appropriate care and adjustments as needed.
Real-world results vs. clinical trial data
While clinical trials provide a controlled look at a drug's efficacy, real-world results give insight into patient satisfaction and long-term use. One of the most compelling findings from the RECONNECT studies was that nearly 80% of women who completed the 24-week core study volunteered to continue treatment in a one-year open-label extension study.
This high continuation rate suggests a strong positive patient experience. It indicates that the women found the improvements in their sexual desire and the reduction in distress meaningful enough to want to continue the therapy. This is a powerful testament to its perceived benefit beyond the structured trial environment.
It is important to remember that Vyleesi is not indicated to enhance sexual performance but to treat HSDD. The enthusiasm for continuing treatment suggests that it successfully addressed the core symptoms of the disorder for many participants, leading to a better quality of life.
Side effects & warnings (BP, nausea, skin changes)
Like all medications, Vyleesi has potential side effects and important safety warnings that you should be aware of. The most common adverse reactions are generally mild to moderate and temporary. Key areas of concern include temporary changes in blood pressure, nausea, and the possibility of skin hyperpigmentation.
Understanding these risks is a critical part of making an informed decision with your healthcare provider. This section breaks down the most common side effects, explains the warnings in detail, and provides guidance on when to seek medical advice.
Most common side effects: nausea, flushing, headache
The most common side effects of Vyleesi reported in clinical trials were generally transient. Nausea is the most frequent adverse event, experienced by 40% of patients. For most, it was mild to moderate and tended to improve after the first dose.
In some cases, nausea was significant enough to require anti-emetic medication (13%) or led to discontinuation of the treatment (8%). Other common side effects include:
-
Flushing (reddening of the skin)
-
Injection site reactions (bruising, pain, or redness)
-
Headache
-
Vomiting
These effects are typically temporary and resolve on their own. However, if you experience severe or persistent nausea or any other concerning side effects, it is important to speak with your healthcare provider. They may be able to suggest ways to manage these reactions.
Blood pressure changes: safety considerations
An important piece of safety information for Vyleesi involves its effect on blood pressure and heart rate. After each dose, Vyleesi can cause a temporary increase in blood pressure and a corresponding decrease in heart rate. These changes typically resolve within 12 hours.
Because of this effect, Vyleesi is contraindicated for women with uncontrolled hypertension or known cardiovascular disease. It is also not recommended for patients considered to be at high risk for cardiovascular events. Your clinician will assess your cardiovascular risk before prescribing the medication.
To minimize this risk, you must not take more than one dose in 24 hours or more than eight doses per month. Adhering strictly to the dosing instructions is essential for using Vyleesi safely and avoiding more pronounced effects on your blood pressure.
Skin hyperpigmentation: when it occurs and risks
A less common but important side effect is focal skin hyperpigmentation, which is a darkening of the skin. This was reported in about 1% of patients in clinical trials. These skin changes can appear on the face, gums, and breasts.
The risk of developing skin hyperpigmentation is higher in women with darker skin. It is also more likely to occur with more frequent dosing, which is why daily use is not recommended. It is a key reason for the limit of eight doses per month.
In some patients, the darkening of the skin did not resolve even after discontinuing Vyleesi. If you notice any unusual skin changes or darkening while using the medication, you should stop treatment and discuss it with your healthcare provider immediately.
Other possible adverse reactions
Beyond the most common side effects, there are other possible side effects associated with Vyleesi that you should be aware of. While less frequent, these adverse reactions were also reported by participants in the clinical studies.
These reactions can include vomiting, cough, fatigue, hot flush, tingling sensations (paresthesia), dizziness, and nasal congestion. Most of these effects are considered mild and tend to pass on their own without requiring specific treatment.
It is helpful to know the full range of potential reactions so you can monitor how you feel after taking a dose. As with any side effect, if you experience anything that is severe, persistent, or worrisome, you should report it to your doctor for further medical advice.
When to discontinue and seek medical advice
Knowing when to stop treatment and seek medical advice is key to using Vyleesi safely. While many side effects are mild, some situations require immediate attention from a healthcare professional. You should always keep this medication out of the reach of children.
Consider discontinuing Vyleesi and consulting your doctor if you experience:
-
Persistent or severe nausea: If nausea does not improve after the first dose or significantly impacts your daily life.
-
Development of hyperpigmentation: If you notice any darkening of your skin on your face, gums, or breasts.
-
Any other serious side effects: If you have a reaction that feels severe or alarming.
Your health and safety are the top priority. Open communication with your provider about how the medication is affecting you will ensure you are using it appropriately and managing any potential risks effectively.
What to discuss with your clinician
Having an open and honest conversation with your healthcare provider is the most important step in determining if Vyleesi is right for you. This discussion should include a complete overview of your medical history, current health status, and any medications you are taking.
Preparing for this conversation can help you get the most out of your appointment. Be ready to talk about your risk factors, potential drug interactions, and what you hope to achieve with treatment. This ensures that the decision is a collaborative one, based on your unique health profile.
Your medical history and risk factors
Before prescribing Vyleesi, your clinician will need to review your complete medical history. This is essential for identifying any risk factors that might make the treatment unsafe for you. Be prepared to discuss your entire health background, even if it seems unrelated.
Of particular importance is your cardiovascular risk. You must inform your doctor if you have a history of high blood pressure, heart problems, kidney disease, or liver problems. Since Vyleesi can temporarily affect blood pressure and heart rate, a thorough cardiovascular assessment is a critical safety step.
Providing this comprehensive history allows your doctor to make an informed decision about whether the benefits of Vyleesi outweigh the potential risks in your specific case. Honesty and completeness are key to ensuring your safety.
Possible drug interactions and alcohol use
Vyleesi can have drug interactions with other medications, so you must tell your provider about everything you take. This includes prescription and over-the-counter medicines, vitamins, and herbal supplements. Vyleesi may slow down the emptying of your stomach, which can affect how other oral medications are absorbed.
One specific and important interaction is with oral naltrexone, a medication used to treat alcohol or opioid addiction. Vyleesi can significantly decrease its effectiveness, so this combination should be avoided. Unlike some other treatments for sexual dysfunction, alcohol use is not contraindicated with Vyleesi.
Providing a full list of your current medications helps your doctor prevent potentially harmful interactions and ensures all your treatments can work effectively and safely together.
Realistic expectations for results
When considering treatment options for sexual desire disorder, it is vital to have realistic expectations. Vyleesi can be an effective tool for many women, but it is not a "magic pill." Its purpose is to help increase your sexual interest and reduce the distress caused by HSDD.
Results can vary from person to person. It is helpful to think of Vyleesi as one part of a broader approach to improving your sexual health. Keep the following points in mind:
-
Vyleesi is designed to increase desire, not guarantee a specific level of sexual activity.
-
The goal is a meaningful improvement in desire and a reduction in distress, not necessarily a return to a previous peak.
-
Most women in studies used it 2-3 times per month, integrating it into their lives as needed.
Discussing your personal goals with your provider can help you understand what a successful outcome might look like for you.
Alternative treatment options for HSDD
Medication is not the only way to address HSDD. There are several alternative treatment options that can be effective, either on their own or in combination with a medication like Vyleesi. A holistic approach to sexual health often yields the best results.
Your provider may recommend exploring other avenues, especially if contributing factors are identified. Some common alternatives include:
-
Counseling or Sex Therapy: This can help address psychological or relationship factors contributing to low desire.
-
Lifestyle Modifications: Managing stress, getting enough sleep, and regular exercise can have a positive impact on libido.
-
Addressing Underlying Conditions: Treating other medical issues, like depression or hormonal imbalances, may resolve the low desire.
These approaches can be powerful tools in your journey toward improved sexual well-being and can complement medical treatment.
Cost, insurance coverage, and accessibility
The cost of a prescription medication is an important consideration for many patients. The accessibility of Vyleesi is supported by various programs designed to make it more affordable. Many commercially insured patients may be eligible for programs that reduce their out-of-pocket expenses.
The manufacturer notes that most eligible patients may pay as little as $0 for their prescription. Here are some key points about cost and insurance coverage:
-
The Vyleesi Co-pay Program is available for eligible patients with commercial insurance.
-
Patients insured by government-funded programs like Medicaid or TRICARE are not eligible for this specific program.
-
The medication is available through a specialty pharmacy partner, BlinkRx, which can help you find the lowest price and provides free shipping.
It is always a good idea to check with your insurance provider to understand your specific coverage and to inquire about patient assistance programs.
Talk to a Healthon clinician about HSDD treatment options
If you believe you are experiencing the symptoms of HSDD, taking the next step and speaking with a qualified healthcare provider is essential. A proper diagnosis is the only way to ensure you receive the right care and explore the most appropriate treatment options for your situation. You don't have to navigate this journey alone; professional medical attention is available to help you understand your symptoms and find a solution.
The clinicians at Healthon are experienced in women's health care and can provide a confidential, comprehensive evaluation. They can help you determine if your low sexual desire is due to HSDD, discuss whether a treatment like Vyleesi is right for you, and answer any questions you may have. Taking control of your sexual health starts with a conversation, so reach out today to book a virtual appointment and get the expert guidance you deserve.
Conclusion
In summary, Bremelanotide, known as Vyleesi, presents a targeted approach for premenopausal women experiencing Hypoactive Sexual Desire Disorder (HSDD). Understanding its mechanism, efficacy, and appropriate usage can empower patients to make informed decisions about their sexual health. With insights from pivotal trials demonstrating significant improvements in sexual desire and reductions in distress, Vyleesi serves as a potential option for those seeking relief. However, it is crucial to consider the side effects and contraindications highlighted within this guide. For those interested in exploring treatment options, we encourage you to sign up for more information and connect with a Healthon clinician to discuss your specific needs and potential pathways to improve your sexual wellness.
Frequently Asked Questions
Is Vyleesi safe for long-term use in women?
The safety information for Vyleesi includes a 52-week open-label extension study, suggesting it can be used longer-term by premenopausal women. However, ongoing monitoring for side effects like skin hyperpigmentation is important. Discuss long-term use with your provider.
Can Vyleesi be used only when needed rather than daily?
Yes. Vyleesi is specifically designed as an as-needed prescription medicine. It is one of the few treatment options for low sexual desire that is taken about 45 minutes before anticipated sexual events, not on a daily schedule.
How does Vyleesi compare to Addyi for treating HSDD?
Vyleesi is an as-needed injection, whereas Addyi is a daily pill for the treatment of HSDD. A key difference is that alcohol use is contraindicated with Addyi due to risks of severe low blood pressure, while it is not with Vyleesi.
How fast does Bremelanotide (Vyleesi) work for HSDD?
Bremelanotide (Vyleesi) typically starts showing effects within 24 to 48 hours after administration. However, individual responses may vary, and some women may notice improvements sooner or later depending on their specific circumstances and health conditions. Always consult your healthcare provider for personalized advice.
Can Bremelanotide be combined with therapy or counseling?
Yes, combining bremelanotide with counseling or sex therapy is often an excellent approach. This combines medical treatment with alternative treatment options that address the psychological and relational aspects of sexual health, potentially leading to better outcomes.
Is Bremelanotide covered by insurance?
Insurance coverage for this prescription medicine varies by plan. Many commercial insurance plans cover it, and the manufacturer offers a co-pay program that may reduce the cost to as little as $0 for eligible patients, improving its accessibility.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
Sources:
-
VYLEESI® [package insert]. South Plainfield, NJ: Cosette Pharmaceuticals, Inc.; 2024. https://vyleesi.com/wp-content/uploads/2024/02/Vyleesi-PI_02.2024.pdf
How much does Bremelanotide cost without insurance?
Bremelanotide costs approximately $3,000 to $5,000 for a month’s supply without insurance. Prices can vary based on the pharmacy and location. It's advisable to check with local pharmacies for specific pricing and available discounts to manage costs effectively.
Who should avoid taking Bremelanotide?
Certain individuals should avoid taking bremelanotide, including those with a history of hypersensitivity to its components, cardiovascular issues, or those who are pregnant or breastfeeding. Consulting a healthcare provider before starting is crucial for safety and suitability.
Reference List
-
Vyleesi. (n.d.). Vyleesi official website. https://vyleesi.com/
-
Mayo Clinic. (2023). Bremelanotide (subcutaneous route) description. https://www.mayoclinic.org/drugs-supplements/bremelanotide-subcutaneous-route/description/drg-20466805
-
WebMD. (n.d.). Bremelanotide (Vyleesi) overview. https://www.webmd.com/drugs/2/drug-4382-5032/pilocarpine-ophthalmic-eye/pilocarpine-solution-ophthalmic/details
-
Vyleesi. (n.d.). Frequently asked questions. https://vyleesi.com/faq/what-do-you-mean-vyleesi-can-be-taken-as-needed/
-
Cleveland Clinic. (n.d.). Bremelanotide for hypoactive sexual desire disorder. https://my.clevelandclinic.org/health/drugs/24375-pilocarpine-eye-solution-presbyopia
-
Palatin Technologies. (2023). Press release: FDA approval of bremelanotide (Vyleesi). https://palatin.com/press_releases/fda-approves-new-drug-application-for-vyleesi-bremelanotide-injection-2/
-
MedlinePlus. (n.d.). Bremelanotide information. https://medlineplus.gov/druginfo/meds/a606004.html
-
Obg Project. (2019, August 2). Prescribing bremelanotide for low desire: How, when, and where. https://www.obgproject.com/2019/08/02/prescribing-bremelanotide-for-low-desire-how-when-and-where/
-
PubMed Central. (2020). Bremelanotide for sexual dysfunction: Mechanisms and clinical outcomes. https://pmc.ncbi.nlm.nih.gov/articles/PMC8412154/
-
Vyleesi. (n.d.). What’s Vyleesi?. https://vyleesi.com/faq/whats-vyleesi/
-
Nature. (1997). Melanocortins and sexual behavior: Clinical and experimental findings. https://www.nature.com/articles/3901200Z
-
Healthline. (2023). Bremelanotide dosage and administration. https://www.healthline.com/drugs/bremelanotide
-
Vyleesi. (n.d.). Who shouldn’t take Vyleesi?. https://vyleesi.com/faq/who-shouldnt-take-vyleesi/
-
Cleveland Clinic. (n.d.). Bremelanotide safety profile. https://my.clevelandclinic.org/health/drugs/24375-pilocarpine-eye-solution-presbyopia
- Insight Ace Analytics. (2022). Bremelanotide and sexual dysfunction treatment: A review. https://www.insightaceanalytic.com/report/bremelanotide-market/
